MALVERN, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today reported financial results for the three and six months ended June 30, 2017.
“We recently achieved a key milestone with the submission of our New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous (IV) meloxicam 30mg, a significant step in our commitment to providing a non-opioid alternative for the management of moderate to severe pain,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. “Based on data from our two pivotal Phase III trials demonstrating efficacy in the moderate to severe, acute pain setting, we believe IV meloxicam 30mg has a unique profile as an effective and well tolerated long-acting therapeutic with the potential to benefit patients and provide physicians with new treatment options.”
